Navidea Biopharma (NAVB) Misses Q4 EPS by 9c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Needham Starts NeoVolta (NEOV) at Buy
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
CORRECTING and REPLACING Navidea Biopharmaceuticals Reports Fourth Quarter 2021 Financial Results
March 23, 2022 3:44 PM EDTConference Call to be held Wednesday, March 23, 2022 at 5:00 pm (EST)
DUBLIN, Ohio--(BUSINESS WIRE)-- This press release is being re-issued to revise the language in the Selling, General and Administrative bullet under Financial Results. That third bullet, third sentence should read: The net increase during the year to date was primarily due to separation expenses related to the resignation... (instead of The net increase during the year to date was primarily due to termination...)
The updated release reads:
NAVIDEA BIOPHARMACEUTICALS REPORTS FOURTH QUARTER 2021 FINANCIAL RESULTS
Conference... More
